A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYALaurie H. Sehn, Umberto Vitolo, Maurizio Martelli et al.|Journal of Hematology & Oncology|2020Cited by 144
Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody TherapyLaura M. Rogers, George J. Weiner, Sarah L. Mott et al.|Clinical Cancer Research|2016Cited by 32
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYASarah C. Rutherford, Peter Martin, Michael Herold et al.|Blood Advances|2020Cited by 23
Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell LymphomaLaurie H. Sehn, Umberto Vitolo, Wenxin Liu et al.|Blood|2019Cited by 11
Table S5 from Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody TherapyLaura M. Rogers, George J. Weiner, Sarah L. Mott et al.|Unknown|2023Cited by 0